Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1983 Sep;53(3):716–724.

Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.

K Funa, G V Alm, L Rönnblom, K Oberg
PMCID: PMC1535658  PMID: 6616963

Abstract

Nine patients with mid-gut carcinoid tumours received leucocyte interferon (IFN) i.m. daily for 90 days. Six patients clearly ameliorated in symptoms typical of the carcinoid syndrome (flushing, diarrhoea, asthma) which correlated with reduced serum levels of tumour related polypeptides and urinary output of 5-hydroxyindole acetic acid (5-HIAA). Before IFN treatment, peripheral blood mononuclear leucocytes (PBLs) from carcinoid patients showed markedly deficient production of pH 2 labile IFN-alpha in response to Staphylococcus aureus Cowan I (SACoI) in vitro. In contrast, IFN-alpha responses to the inducers Sendai virus and beta-haemolytic streptococcus group G and IFN-gamma responses to Lens culinaris lectin and concanavalin A were normal. Also, basal and in vitro IFN enhanced natural killer (NK) cell activity and T cell mitogen-induced cell proliferation were similar in patients and controls. During 90 days of IFN therapy, SACoI-induced IFN responses became entirely undetectable. There were transient declines at 1 and 30 days in IFN responses to the other IFN inducers, of mitogen-induced lymphocyte proliferation and of basal NK activities. The increments of NK cell activities after in vitro IFN exposure were clearly decreased in IFN treated patients, suggesting in vivo activation of these cells. Thus, the results demonstrate one remarkable abnormality in carcinoid patients: a deficient IFN response to SACoI and a clear influence of IFN therapy on several parameters of the IFN-NK system.

Full text

PDF
716

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borden E. C., Holland J. F., Dao T. L., Gutterman J. U., Wiener L., Chang Y. C., Patel J. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med. 1982 Jul;97(1):1–6. doi: 10.7326/0003-4819-97-1-1. [DOI] [PubMed] [Google Scholar]
  2. DeBoer K. P., Braun D. P., Harris J. E. Natural cytotoxicity and antibody-dependent cytotoxicity in solid tumor cancer patients: regulation by adherent cells. Clin Immunol Immunopathol. 1982 Apr;23(1):133–144. doi: 10.1016/0090-1229(82)90078-2. [DOI] [PubMed] [Google Scholar]
  3. Einhorn S., Ahre A., Blomgren H., Johansson B., Mellstedt H., Strander H. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer. 1982 Aug 15;30(2):167–172. doi: 10.1002/ijc.2910300207. [DOI] [PubMed] [Google Scholar]
  4. Einhorn S., Blomgren H., Strander H. Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer. 1978 Oct 15;22(4):405–412. doi: 10.1002/ijc.2910220407. [DOI] [PubMed] [Google Scholar]
  5. Feldman J. M., Plonk J. W., Cornette J. C. Serum prostaglandin F-2 alpha concentration in the carcinoid syndrome. Prostaglandins. 1974 Sep 25;7(6):501–506. doi: 10.1016/0090-6980(74)90094-x. [DOI] [PubMed] [Google Scholar]
  6. Fisher R. I., Mandell G. L., Bostick F., McMenamin M. G., Anderson T. Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice. Clin Exp Immunol. 1980 Feb;39(2):416–425. [PMC free article] [PubMed] [Google Scholar]
  7. Herberman R. B. Immunoregulation and natural killer cells. Mol Immunol. 1982 Oct;19(10):1313–1321. doi: 10.1016/0161-5890(82)90299-1. [DOI] [PubMed] [Google Scholar]
  8. Kadish A. S., Doyle A. T., Steinhauer E. H., Ghossein N. A. Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol. 1981 Nov;127(5):1817–1822. [PubMed] [Google Scholar]
  9. Kariniemi A. L., Timonen T., Kousa M. Effect of leucocyte interferon on natural killer cells in healthy volunteers. Scand J Immunol. 1980;12(5):371–374. doi: 10.1111/j.1365-3083.1980.tb00080.x. [DOI] [PubMed] [Google Scholar]
  10. Ojo-Amaize E. A., Salimonu L. S., Williams A. I., Akinwolere O. A., Shabo R., Alm G. V., Wigzell H. Positive correlation between degree of parasitemia, interferon titers, and natural killer cell activity in Plasmodium falciparum-infected children. J Immunol. 1981 Dec;127(6):2296–2300. [PubMed] [Google Scholar]
  11. Peter H. H., Dallügge H., Zawatzky R., Euler S., Leibold W., Kirchner H. Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum. Eur J Immunol. 1980 Jul;10(7):547–555. doi: 10.1002/eji.1830100712. [DOI] [PubMed] [Google Scholar]
  12. Riesenfeld I., Orn A., Gidlund M., Axberg I., Alm G. V., Wigzell H. Positive correlation between in vitro NK activity and in vivo resistance towards AKR lymphoma cells. Int J Cancer. 1980 Mar 15;25(3):399–403. doi: 10.1002/ijc.2910250315. [DOI] [PubMed] [Google Scholar]
  13. Rönnblom L., Forsgren A., Alm G. V. Characterization of interferons induced by bacteria and interferon-producing leukocytes in human peripheral blood. Infect Immun. 1983 Apr;40(1):126–132. doi: 10.1128/iai.40.1.126-132.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rönnblom L., Funa K., Ersson B., Alm G. V. Lectins as inducers of interferon-gamma production in human lymphocytes: lentil lectin is highly efficient. Scand J Immunol. 1982 Oct;16(4):327–331. doi: 10.1111/j.1365-3083.1982.tb00731.x. [DOI] [PubMed] [Google Scholar]
  15. Rönnblom L., Ojo-Amaize E. A., Franzén L., Wigzell H., Alm G. V. Plasmodium falciparum parasites induce interferon production in human peripheral blood 'null' cells in vitro. Parasite Immunol. 1983 Mar;5(2):165–172. doi: 10.1111/j.1365-3024.1983.tb00734.x. [DOI] [PubMed] [Google Scholar]
  16. Saksela E., Timonen T., Cantell K. Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells. Scand J Immunol. 1979;10(3):257–266. doi: 10.1111/j.1365-3083.1979.tb01348.x. [DOI] [PubMed] [Google Scholar]
  17. Sandler M., Karim S. M., Williams E. D. Prostaglandins in amine-peptide-secreting tumours. Lancet. 1968 Nov 16;2(7577):1053–1054. doi: 10.1016/s0140-6736(68)91528-6. [DOI] [PubMed] [Google Scholar]
  18. Sikora K. Does interferon cure cancer? Br Med J. 1980 Sep 27;281(6244):855–858. doi: 10.1136/bmj.281.6244.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Targan S. R. The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and blockage of pre-NK cell recruitment. J Immunol. 1981 Oct;127(4):1424–1428. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES